VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (... ( -- Top-Line Data Expecte...)

VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial

Date:7/10/2008

-- Top-Line Data Expected in the Third Quarter --

SAN FRANCISCO, July 10 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed the last patient visit in its carotid endarterectomy (CEA) study. The excised carotid plaque tissue will be analyzed to determine VIA-2291's effect on inflammation, and the company remains on track to report top-line data in the third quarter.

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events associated with inflammation, including heart attack and stroke.

"Analyzing the carotid plaque collected in the CEA trial is a novel approach to aid investigators in the evaluation of VIA-2291's potential impact on inflammation," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "Our Phase 2 program, which includes this trial as well as two others, is designed to provide proof-of-concept evidence supporting the potential effectiveness of VIA-2291 and its further development."

The CEA study enrolled 50 patients and is designed to provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries of patients treated with VIA-2291 or placebo. CEA is a surgical procedure to remove plaque from the carotid artery to increase blood flow to the brain in patients with significant blockage in the artery to reduce the risk of stroke. Patients in the study are treate
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
2. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
5. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
6. Isis Pharmaceuticals Conference Call Notice
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
9. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis

Post Your Comments:

(Date:5/21/2013)... 21, 2013 Valeant Pharmaceuticals ... ) (TSX: VRX) today announced the ... its 2013 annual meeting of shareholders ... vote for the election of directors ... Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason Morfit235,623,2832,073,399J. ...

(Date:5/21/2013)... EAST TAUNTON, Massachusetts , 21 de mayo de ... Synergy, Inc. ("OSI"), cuyas compañías filiales incluyen OMNIlife ... a dos directores experimentados para su junta. Guy Mayer, ... junta directiva y David Johnson ... unirá como director. Antes de unirse ...

(Date:5/21/2013)... and PHILADELPHIA , May 21, 2013 ... its new corporate image and impressive new product developments at ... . "After ten years of unerring focus on product ... felt the need to mark the occasion," said founding director ... we have some interesting developments of benefit to our clients ...

Breaking Medicine Technology:Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2 Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2 Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3 Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2 Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3

[0] Valeant Pharmaceuticals Announces 2013 Annual Meeting Results [0] Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva [0] Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia

... (Nasdaq: IDEV ) today announced that it ... and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a sterile ... product approved by the FDA for therapy of,bacillus ... bladder. VALSTAR was removed from the market ...

... 17 Dendreon Corporation,(Nasdaq: DNDN ) today ... study,of NEUVENGE, an investigational active cellular immunotherapy, in ... Oncology. The article highlights,the safety profile, immune response ... breast cancer who have failed standard,therapy. "In ...

Cached Medicine Technology:Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2 Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3 Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

(Date:5/22/2013)... from a large observational study reported at ... superior to heparin in the absence of ... patients with non-ST segment elevation acute coronary ... European and US NSTE-ACS guidelines currently recommend ... heparin plus GP IIb/IIIa receptor inhibitors in ...

(Date:5/22/2013)... MA (PRWEB) May 22, 2013 In ... hit the country’s fields and courts with donated ... Sports, a Massachusetts-based nonprofit dedicated to partnering with manufacturers ... is celebrating the donation of $8.8 million in sports ... more than a half-million kids outfitted for physical activity. ...

(Date:5/22/2013)... Following the success of last year’s ... Fit Body Boot Camp Kincardine has announced it will ... starting on June 3rd at its Kincardine fitness ... Kincardine, Ontario. , Fit Body Boot Camp’s 1,000 lb. ... community residents to lose a total of 1,000 pounds ...

(Date:5/22/2013)... Jersey City, NJ (PRWEB) May 22, 2013 ... governance, compliance, and management solutions for social enterprise ... Partners, LLC, a consulting firm based in Chicago, ... to integrate their products and provide best-in-class solutions ... productivity and improve collaboration. , AvePoint’s DocAve ...

(Date:5/22/2013)... adherence to appropriate medication therapy has been shown to ... 125,000 deaths in the U.S. every year are attributed ... estimated that between 33% and 69% of all medication-related ... a reality that costs the American health-care system approximately ... degree of medication non-adherence — and the consequences therefrom ...

Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2 Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2 Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3 Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2 Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3 Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2

[0] Registry questions superiority of bivalirudin over heparin [0] Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity [0] Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity [0] AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration [0] Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance

... 25 Former NFL player and Dallas Cowboy,Jason Kaiser ... graduation ceremony. Kaiser earned the title of,valedictorian with a ... people in,this school and in my class especially," he ... Before enrolling in Parker College, Kaiser played professional football,for ...

... protein levels could key future treatments for Alzheimer,s , , ... finds that where protein-destroying machines reside in the brain,s ... a finding that may play a role in future ... Wake Forest University School of Medicine researchers studying mice ...

... his left eyebrow was possibly skin cancer , , FRIDAY, ... during his lifetime, historians have gone to great lengths ... of Franklin Delano Roosevelt, the 32nd president of the ... and heart disease is now well-documented. But a new ...

... QLT Inc. (NASDAQ: QLTI;,TSX: QLT) today reported financial results ... otherwise, all amounts are in U.S. dollars,and in accordance ... 2008, we were pleased to report the U.S. Food,and ... blood,monitoring from the Aczone(TM) label," said Bob Butchofsky, President ...

... Inc., (a wholly owned,subsidiary of Mentice AB), a ... the field of medicine, has recently appointed,Jeff Sirek ... Clinical,Applications Manager for the Americas., Jeff Sirek ... years with GE Healthcare in its Cardiovascular Ultrasound,Division ...

... Solutions, Inc. announced,today the addition of Dr. Marc ... serve as Vice President of Research and Development ... of spine,system/orthopedic development experience, most recently having directed,development ... Marc to Facet Solutions bolsters an already great,team, ...

Former Dallas Cowboy Honored as Parker College of Chiropractic Top 2008 Graduate When It Comes to Memory, It's All About Location FDR Might Have Had Melanoma QLT announces first quarter results for 2008 Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.Facet Solutions, Inc. Expands Executive Management Team

... is a fully automatic fluorescence photomicrography system ... of even the most difficult specimens. Designed ... PM20 system provide solution to the complex ... their automatic exposure control, the system utilizes ...

... in the PM series is designed ... for routine brightfield observation, both in ... Remarkably economical in,price, it offers a ... which meet the needs of todays ...

... camera system for high resolution photomicrography. The ... of the highest color fidelity, resolution and ... expect perfect images due to many unique ... innovative readout modes. The Leica DFC480 is ...

This compact photomicrographic system assures simple operation to achieve the exposure accuracy required for sophisticated photomicrography in most research and clinical environments....

Medicine Products:

PM20 Automatic Photomicrography System PM10SP Automatic Photomicrography System Leica DFC480 H-III Auto-Photomicrographic Film Camera